Home
Technology
About us
News
Contact
News
home
news
Dr. Mahmood Nazari was appointed CEO of PharmAI Discovery GmbH on July 1. With a PhD from TU Dresden and more than ten years of experience in the pharmaceutical industry, he brings a strong background at the intersection of artificial intelligence, nuclear medicine, and drug development. His expertise and leadership will guide PharmAI Discovery into its next phase of growth and further advance our AI-driven approach to drug discovery.
Together we’re developing hybrid quantum–classical methods to boost protein–ligand modeling, combining PharmAI’s AI-driven discovery with TU Dresden’s quantum expertise. (18 Sep 2025)
PharmAI Discovery Secures €5 Million to Accelerate AI-Powered Drug Pipeline (26 Feb 2025)
PharmAI Discovery Joins EU-Funded APPEAL Project to Fast-Track Host-Targeted Antivirals (May 2025)
PharmAI Discovery Partners with Enamine & Chemspace to Expand AI-Driven Theranostic Pipeline
PharmAI Discovery Files Two Patent Families for LDH-Tetramer Disruptors, Opening a New Front in Cancer Metabolism (Oct 2024)
AI-Designed HSP27 Neuro-Protective Inhibitors Advance Toward Pre-Clinical GLP Studies at PharmAI Discovery
